Last updated: February 24, 2026
What is the Drug Compressed?
NDC 71930-0010 corresponds to Xyrem (sodium oxybate), a central nervous system depressant indicated primarily for the treatment of narcolepsy with cataplexy. It is marketed by Jazz Pharmaceuticals.
Market Size and Trends
Key Market Data:
| Metric |
Data |
| Global narcolepsy prevalence |
10-20 per 100,000 adults worldwide |
| U.S. market size (2022) |
Approx. $600 million in prescription sales (IQVIA) |
| Patients eligible for Xyrem |
Estimated 25,000-30,000 in the U.S. |
Growth Drivers:
- Increased diagnosis rates of narcolepsy.
- Expanded off-label uses for conditions like fibromyalgia, sleep apnea.
- Rising awareness leading to higher prescription volume.
Competitive Landscape:
- Xyrem holds approximately 85% share of the narcolepsy-specific treatment market.
- Other therapies include sodium oxybate formulations by generic manufacturers, although their market penetration remains limited due to regulatory restrictions.
Regulatory and Pricing Framework
Pricing:
- Average wholesale price (AWP): Approximately $30 to $35 per mL.
- Monthly cost for a typical dose (50 mL): $1,500 to $1,750.
- Patient out-of-pocket cost varies significantly with insurance coverage; copays often range from $25 to $150 per month.
Reimbursement:
- Covered by Medicare and most commercial insurers.
- Prior authorization is generally required due to abuse potential and scheduling restrictions.
Patent and Exclusivity:
- Xyrem received orphan drug designation.
- Patent exclusivity periods extended until at least 2024.
- Generic sodium oxybate formulations are limited by regulatory hurdles, delaying price erosion.
Price Projections
Short-Term (Next 1-2 Years):
- Price stability expected due to patent protections and limited generics.
- Wholesale acquisition costs (WAC) projected to remain in the $30-$35 per mL range.
- Medicare and insurer negotiation pressures unlikely to significantly reduce patient costs immediately.
Medium to Long-Term (3-5 Years):
- Introduction of generics could reduce prices by 30-50%, depending on regulatory approval timelines and market penetration.
- Patent expiry forecasted for 2024, with generics entering the market in 2025.
- Price erosion anticipated to depress total drug revenue by 20-40% over five years post-generic entry.
Factors Influencing Long-Term Pricing:
- Regulatory barriers to generic approval.
- Negotiation power of payers.
- Development of alternative therapies reducing demand.
- Future patent or exclusivity extensions.
Market Entry Barriers and Risks
- Strict scheduling as a Schedule III controlled substance complicates manufacturing and distribution.
- High abuse potential leads to tight regulatory oversight.
- Limited manufacturing capacity constrains rapid generic entry.
Key Takeaways
- NDC 71930-0010, marketed as Xyrem, has a stabilized pricing environment due to patent protections and limited competition.
- The U.S. narcolepsy market for Xyrem is valued around $600 million annually.
- Expected generic entry in 2025 could lead to significant price reductions, impacting revenue.
- Reimbursement complexities and regulatory controls influence patient access and cost.
- Market growth depends on increased diagnosis, expanded indications, and competitive landscape shifts.
FAQs
1. What factors could influence changes in Xyrem’s price within the next five years?
Market entry of generics, regulatory decisions, reimbursement negotiations, and developments in alternative therapies.
2. How does patent expiration affect the market for sodium oxybate formulations?
Patents expiring around 2024 will enable generic manufacturers to produce lower-cost versions, decreasing overall market prices.
3. Are there approved alternatives to Xyrem for narcolepsy treatment?
Yes, including wakefulness-promoting agents like modafinil and armodafinil; however, none match the efficacy of sodium oxybate for cataplexy symptoms.
4. What are the implications of pricing strategies for payers?
Price stability limits immediate costs; future generic competition may prompt negotiations for discounts or formulary limits.
5. How do regulatory controls impact the manufacturing and distribution of sodium oxybate?
Stringent scheduling and abuse-deterrent measures complicate supply chain logistics and delay generic market entry.
References
- IQVIA. (2022). U.S. Prescription Market Data.
- Jazz Pharmaceuticals. (2022). Xyrem Product Data.
- Food and Drug Administration (FDA). (2022). Drug Approvals and Patent Data.
- MarketWatch. (2023). Pharmaceutical Market Trends.
- Medscape. (2021). Narcolepsy and Treatment Options.
Note: All figures are estimates based on current public data sources. Actual prices and market size may vary with future developments.
